Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 papers


  Multiple Sclerosis

  Free Subscription


1 Acta Neurol Scand
1 Arch Phys Med Rehabil
1 Can J Neurol Sci
2 J Neurol
1 J Neurol Neurosurg Psychiatry
1 J Neurol Sci
1 Mult Scler
1 Nat Med
1 Nervenarzt
3 PLoS One
1 Rev Neurol
1 Rev Neurol (Paris)

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Neurol Scand

  1. ZARGHAMI A, Nourmohammadi ST, Hojjati SMM
    Urbanization theory and socioeconomic changeover of multiple sclerosis in Iran.
    Acta Neurol Scand. 2020;141:256.

    Arch Phys Med Rehabil

  2. KELLERMAN QD, Hartoonian N, Beier ML, Leipertz SL, et al
    Risk Factors for Suicide in a National Sample of Veterans with Multiple Sclerosis.
    Arch Phys Med Rehabil. 2020 Apr 20. pii: S0003-9993(20)30211.
    PubMed         Abstract available

    Can J Neurol Sci

    Navigating the TOR of multiple sclerosis.
    Can J Neurol Sci. 2020 Apr 24:1-7. doi: 10.1017/cjn.2020.

    J Neurol

  4. MATEEN FJ, Vogel AC, Kaplan TB, Hotan GC, et al
    Light therapy for multiple sclerosis-associated fatigue: a randomized, controlled phase II trial.
    J Neurol. 2020 Apr 24. pii: 10.1007/s00415-020-09845.
    PubMed         Abstract available

  5. MISICKA E, Sept C, Briggs FBS
    Predicting onset of secondary-progressive multiple sclerosis using genetic and non-genetic factors.
    J Neurol. 2020 Apr 24. pii: 10.1007/s00415-020-09850.
    PubMed         Abstract available

    J Neurol Neurosurg Psychiatry

    Distribution of plaques in the cerebrum in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Apr 20. pii: jnnp-2019-322431.

    J Neurol Sci

  7. FALSAFI Z, Tafakhori A, Agah E, Mojarrad M, et al
    Safety and efficacy of memantine for multiple sclerosis-related fatigue: A pilot randomized, double-blind placebo-controlled trial.
    J Neurol Sci. 2020;414:116844.
    PubMed         Abstract available

    Mult Scler

  8. KALB R, Brown TR, Coote S, Costello K, et al
    Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course.
    Mult Scler. 2020 Apr 23:1352458520915629. doi: 10.1177/1352458520915629.
    PubMed         Abstract available

    Nat Med

    Medical euthanasia brings new questions for researchers.
    Nat Med. 2020;26:152-154.


  10. KRAFT AK, Berger K
    [Core aspects of a needs-conform care of patients with multiple sclerosis : Utilization of outpatient services and shared decision making].
    Nervenarzt. 2020 Apr 24. pii: 10.1007/s00115-020-00906.
    PubMed         Abstract available

    PLoS One

  11. GOITIA B, Bruno D, Abrevaya S, Sedeno L, et al
    The relationship between executive functions and fluid intelligence in multiple sclerosis.
    PLoS One. 2020;15:e0231868.
    PubMed         Abstract available

  12. PARRAVICINI C, Lecca D, Marangon D, Coppolino GT, et al
    Development of the first in vivo GPR17 ligand through an iterative drug discovery pipeline: A novel disease-modifying strategy for multiple sclerosis.
    PLoS One. 2020;15:e0231483.
    PubMed         Abstract available

  13. SAURI-SUAREZ S, Quinones-Aguilar S, Contreras-Marin A, Ramiro-Guerrero EO, et al
    Adherence to self-administering interferon-beta1a using RebiSmart(R) device in Mexican patients with relapsing multiple sclerosis.
    PLoS One. 2020;15:e0230959.
    PubMed         Abstract available

    Rev Neurol

  14. COSTA-FROSSARD L, Moreno-Torres I, Meca-Lallana V, Garcia-Dominguez JM, et al
    [EMCAM (Multiple Sclerosis Autonomous Community of Madrid) document for the management of patients with multiple sclerosis during the SARS-CoV-2 pandemic].
    Rev Neurol. 2020;70:329-340.
    PubMed         Abstract available

    Rev Neurol (Paris)

    Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? No.
    Rev Neurol (Paris). 2020 Apr 22. pii: S0035-3787(20)30494.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.